Demonstration of Apoptosis-associated Cleavage Products of DNA, Complement Activation Products SC5b-9 and C3d/dg, and Immune Complexes CIC-C3d, CIC-IgA, and CIC-IgG in the Urine of Patients with Membranous Glomerulonephritis

Croatian Medical Journal

Volumn 44, Issue 6, 2003, Pages 707-711

  Kotnik, Vladimir ^a   Premzl, Aleš ^d   Škoberne, Mojca ^a   Malovrh, Tadej ^a   Kveder, Radoslav ^b   Kaplan Pavlovčič, Staša ^b   Kotnik, Antonija ^c   Štiblar Martinčič, Draga ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

^d JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

Apoptosis; Complement activation; Glomerulonephritis, membranous; Immunoassay; Urine

Indexed keywords

APOPTOSIS INDUCING FACTOR; COMPLEMENT COMPONENT C3D; IMMUNOGLOBULIN A; MEMBRANE PROTEIN;

ADULT; AGED; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; CELL TRANSPORT; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEX FORMATION; DNA CLEAVAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE COMPLEX DISEASE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PERMEABILITY; MEMBRANOUS GLOMERULONEPHRITIS; NUCLEOSOME; URINALYSIS;

ADULT; AGED; ANTIGEN-ANTIBODY COMPLEX; APOPTOSIS; CELL DIVISION; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT SYSTEM PROTEINS; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; REPRESSOR PROTEINS;

EID: 0347090246     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Couser WG. Pathogenesis of glomerulonephritis. Kidney Int Suppl 1993;42:S19-26.
2. Kirschfink M. Controlling the complement system in inflammation. Immunopharmacology 1997;38:51-62.
3. Kumar V, Cotran RS, Robbins SL. Basic pathology. 6th ed. Philadelphia (PA): WB Saunders Co.; 1997.
4. Wakayama H, Hasegawa Y, Kawabe T, Hara T, Matsuo S, Mizuno M, et al. Abolition of anti-glomerular basement membrane antibody-mediated glomerulonephritis in FcRgamma-deficient mice. Eur J Immunol 2000;30:1182-90.
5. Van Dixhoorn MG, Salazar-Exaire D, Sato T, Daha MR, Quigg RJ, Bruijn JA, et al. Anti-vitronectin antibodies enhance anti-Thy-1-induced proteinuria in PVG/c, but not in Wistar rats. J Am Soc Nephrol 1998;9:994-1007.
6. Couser WG, Baker PJ, Adler S. Complement and the direct mediation of immune glomerular injury: a new perspective. Kidney Int 1985;28:879-90.
7. Couser WG. Glomerular injury induced by the SC5b-9 membrane attack complex of complement. In: Hatano M. Nephrology. Tokyo: Springer Verlag; 1991. p. 182-90.
8. Couser WG, Schulze M, Pruchno CJ. Role of C5b-9 in experimental membranous nephropathy. Nephrol Dial Transplant 1992;7 Suppl 1:25-31.
9. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 1999;10:2323-31.
10. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 2002;4:449-60.
11. Kon SP, Coupes B, Short CD, Solomon LR, Raftery MJ, Mallick NP, et al. Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy. Kidney Int 1995;48:1953-8.
12. Bechtel U, Scheuer R, Landgraf R, Konig A, Feucht HE. Assessment of soluble adhesion molecules (sICAM-1, sVCAM-1, sELAM-1) and complement cleavage products (sC4d, sC5b-9) in urine. Clinical monitoring of renal allograft recipients. Transplantation 1994;58:905-11.
13. Honkanen E, Teppo AM, Meri S, Lehto T, Gronhagen-Riska C. Urinary excretion of cytokines and complement SC5b-9 in idiopathic membranous glomerulonephritis. Nephrol Dial Transplant 1994;9:1553-9.
14. Brenchley PE, Coupes B, Short CD, O'Donoghue DJ, Ballardie FW, Mallick NP. Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney Int 1992;41:933-7.
15. Kerjaschki D, Schulze M, Binder S, Kain R, Ojha PP, Susani M, et al. Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy. J Immunol 1989;143:546-52.
16. Kerjaschki D. Pathogenetic concepts of membranous glomerulopathy (MGN). J Nephrol 2000;13 Suppl 3:S96-100.
17. Mayer M. Complement and complement fixation. In: Kabat EA, Mayer MM, editors. Experimental immunochemistry. Springfield (IL): Charles C. Thomas Publisher; 1961. p. 133-240.
18. Joiner KA, Hawiger A, Gelfand JA. A study of optimal reaction conditions for an assay of the human alternative complement pathway. Am J Clin Pathol 1983;79:65-72.
19. Accardo-Palumbo A, Triolo G, Casiglia D, Salli L, Giardina E. Two-site ELISA for quantification of the terminal C5b-9 complement complex in plasma. Use of monoclonal and polyclonal antibodies against a neoantigen of the complex. J Immunol Methods 1993;163:169-72.
20. Deppisch R, Schmitt V, Bommer J, Hansch GM, Ritz E, Rauterberg EW. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int 1990;37:696-706.
21. Brandslund I, Siersted HC, Svehag SE, Teisner B. Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma. J Immunol Methods 1981;44:63-71.
22. Triolo G, Giardina E, Rinaldi A, Bompiani GD. IgA-and insulin-containing (C3-fixing) circulating immune complexes in diabetes mellitus. Clin Immunol Immunopathol 1984;30:169-77.
23. Triolo G, Traina M, Giardina E, Galluzzo A, Rinaldi A, Raineri A. Circulating immune complexes containing IgG, IgA and IgM in patients with myocardial infarction: detection with C1qSP and anti C3SP. J Clin Lab Immunol 1984;13:35-9.
24. Doi T, Kanatsu K, Nagai H, Suehiro F, Kuwahara T, Hamashima Y. Demonstration of C3d deposits in membranous nephropathy. Nephron 1984;37:232-5.
25. Falk RJ, Dalmasso AP, Kim Y, Tsai CH, Scheinman JI, Gewurz H, et al. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest 1983;72:560-73.
26. Kusunoki Y, Akutsu Y, Itami N, Tochimaru H, Nagata Y, Takekoshi Y, et al. Urinary excretion of terminal complement complexes in glomerular disease. Nephron 1991;59:27-32.
27. Coupes BM, Kon SP, Brenchley PE, Short CD, Mallick NP. The temporal relationship between urinary C5b-9 and C3dg and clinical parameters in human membranous nephropathy. Nephrol Dial Transplant 1993;8:397-401.
28. Montinaro V, Lopez A, Monno R, Cappiello V, Manno C, Gesualdo L, et al. Renal C3 synthesis in idiopathic membranous nephropathy: correlation to urinary C5b-9 excretion. Kidney Int 2000;57:137-46.
29. Hansch GM, Schieren G, Wagner C, Schonermark M. Immune damage to the mesangium: antibody- and complement-mediated stimulation and destruction of mesangial cells. J Am Soc Nephrol 1992;2(10 Suppl):S139-43.
30. Hogasen AK, Overlie I, Hansen TW, Abrahamsen TG, Finne PH, Hogasen K. The analysis of the complement activation product SC5 b-9 is applicable in neonates in spite of their profound C9 deficiency. J Perinat Med 2000;28:39-48.
31. Camussi G, Ronco C, Montrucchio G, Piccoli G. Role of soluble mediators in sepsis and renal failure. Kidney Int Suppl 1998;66:S38-42.
32. Kraus S, Fishelson Z. Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C. Eur J Immunol 2000;30:1272-80.
33. Lianos EA, Zanglis A. Effects of complement activation on platelet-activating factor and eicosanoid synthesis in rat mesangial cells. J Lab Clin Med 1992;120:459-64.
34. Lehto T, Honkanen E, Teppo AM, Meri S. Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis. Kidney Int 1995;47:1403-11.
35. Wagner C, Braunger M, Beer M, Rother K, Hansch GM. Induction of matrix protein synthesis in human glomerular mesangial cells by the terminal complement complex. Exp Nephrol 1994;2:51-6.
36. Nauta AJ, Daha MR, Tijsma O, van de Water B, Tedesco F, Roos A. The membrane attack complex of complement induces caspase activation and apoptosis. Eur J Immunol 2002;32:783-92.
37. Rus HG, Niculescu FI, Shin ML. Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev 2001;180:49-55.
38. Sato T, Van Dixhoorn MG, Prins FA, Mooney A, Verhagen N, Muizert Y, et al. The terminal sequence of complement plays an essential role in antibody-mediated renal cell apoptosis. J Am Soc Nephrol 1999;10:1242-52.
39. Couser WG. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant 1998;13 Suppl 1:10-5.
40. Bohler T, Waiser J, Hepburn H, Gaedeke J, Lehmann C, Hambach P, et al. TNF-alpha and IL-1alpha induce apoptosis in subconfluent rat mesangial cells. Evidence for the involvement of hydrogen peroxide and lipid peroxidation as second messengers. Cytokine 2000;12:986-91.
41. Hughes J, Nangaku M, Alpers CE, Shankland SJ, Couser WG, Johnson RJ. C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis. Am J Physiol Renal Physiol 2000;278:F747-57.
42. Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Ohashi R, Sugisaki Y, et al. Complement-mediated killing of mesangial cells in experimental glomerulonephritis: cell death by a combination of apoptosis and necrosis. Nephron 2000;86:152-60.
43. Kashihara N, Sugiyama H, Makino H. Mechanisms for induction of apoptosis and glomerular disease. Nephrol Dial Transplant 1999;14 Suppl 1:52-4.
44. Jeruc J, Jurcic V, Vizjak A, Hvala A, Babic N, Kveder R, et al. Tubulo-interstitial involvement in lupus nephritis with emphasis on pathogenesis. Wien Klin Wochenschr 2000;112:702-6.
45. Kveder R, Kanolus A, Bren AF, Kovac J, Sega S. The effect of kidney transplantation on autonomic nervous dysfunction in patients with chronic renal failure. Transplant Proc 2001;33:3394-5.
46. Zidar N, Ferluga D, Volavsek M, Vizjak A, Luzar S, Kveder R. Renal extraglomerular vascular immune deposits in IgA glomerulonephritis. Kidney Int 1992;42:1444-9.
47. Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota Z. Reactive oxygen species induce apoptosis in cultured human mesangial cells. J Am Soc Nephrol 1996;7:2357-63.
48. Sugiyama H, Kashihara N, Maeshima Y, Okamoto K, Kanao K, Sekikawa T, et al. Regulation of survival and death of mesangial cells by extracellular matrix. Kidney Int 1998;54:1188-96.
49. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995;181:1235-8.
50. Itoh N, Tsujimoto Y, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 1993;151:621-7.
51. Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW, Greenberg AH. Premature p34cdc2 activation required for apoptosis. Science 1994;263:1143-5.
52. Wenzel-Seifert K, Lentzen H, Seifert R. In U-937 promonocytes, misteltoe lectin I increases basal [Ca2+]i, enhances histamine H1- and complement C5a-receptor-mediated rises in [Ca2+]i, and induces cell death. Naunyn Schmiedebergs Arch Pharmacol 1997;355:190-7.